Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (10): 1611-1615.doi: 10.16352/j.issn.1001-6325.2022.10.1611

• Mini Reviews • Previous Articles     Next Articles

Research progress on botulinum toxin type A in the treatment of Raynaud's phenomenon

WANG Yuan-zhuo, ZHENG Qing-yue, ZHANG Han-lin, TANG Ke-yun, FANG Rou-yu, SUN Qiu-ning*   

  1. Department of Dermatology, Peking Union Medical College Hospital,CAMS & PUMC, Beijing 100730, China
  • Received:2020-12-17 Revised:2021-05-06 Online:2022-10-05 Published:2022-09-23
  • Contact: *

Abstract: Raynaud's phenomenon is a common vasospasm response, and current medical therapies and surgical treatments show limited clinical effects. Botulinum toxin type A has certain effectiveness and safety in treating Raynaud's phenomenon. It can relax blood vessels, relieve pain, and has a good long-term effect. Its side effects are mild, such as pain at the injection site, bruises, or transient muscle weakness. In recent years, some research has broadened the scope of application of the treatment and determined more effective injection doses and injection methods to reduce the side effects. More large-sample randomized double-blind controlled trials and animal experiments are needed to provide information for explaining the treatment mechanisms and illstrating the efficacy.

Key words: Raynaud's phenomenon, botulinum toxin type A

CLC Number: